Affiliation:
1. CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad 500007, Telangana, India
2. AcSIR-Academy of Scientific and Innovative Research, Ghaziabad 201002, Uttar Pradesh, India
Abstract
Abstract:
Amyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor
neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the
clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not
been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective
in slowing the disease progression. Over the last 15 years, there has been a rapid advancement
in research on the complex pathomechanistic landscape of ALS that has opened up new avenues for
successful clinical translation of targeted therapeutics. Multiple studies suggest that the age-dependent
interaction of risk-associated genes with environmental factors and endogenous modifiers is critical to
the multi-step process of ALS pathogenesis. In this review, we provide an updated discussion on the
dysregulated cross-talk between intracellular homeostasis processes, the unique molecular networks
across selectively vulnerable cell types, and the multisystemic nature of ALS pathomechanisms. Importantly,
this work highlights the alteration in epigenetic and epitranscriptomic landscape due to
gene-environment interactions, which have been largely overlooked in the context of ALS pathology.
Finally, we suggest that precision medicine research in ALS will be largely benefitted from the stratification
of patient groups based on the clinical phenotype, onset and progression, genome, exposome,
and metabolic identities.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology,General Medicine